Median Technologies is a high-risk, high-upside medical AI inflection story: a stable iCRO backlog funds the bridge while FDA-cleared eyonis® LCS attempts to transform the company into a scalable diagnostic software platform.
Overview
Median Technologies is transitioning from an AI-enabled clinical-trial imaging services provider into a scalable diagnostic AI software company. Today, 100% of revenue comes from the iCRO segment, which serves global biopharma customers across oncology trials. The major growth engine is eyonis® LCS, an FDA-cleared lung cancer screening SaMD with strong reported sensitivity, specificity, and 99.9% negative predictive value. Commercial success depends on converting regulatory clearance, reimbursement, and the Tempus AI partnership into U.S. clinical adoption beginning in 2026.